Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Neuroblastoma × eliglustat × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 1

Interventions

gallium Ga 68 dotatate 2 naxitamab 1 fludarabine 1 eliglustat 1 Vaccines, DNA 1 Thiotepa 1 Temozolomide 1 Rituximab 1 Magnetic Resonance Spectroscopy 1 Lenalidomide 1 Irinotecan 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Ga(III)-DOTATOC 1 6-fluorodopamine 1 3-fluorobenzylguanidine 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07090538 2025-07-29

GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.

Chinese PLA General Hospital

Phase EARLY_PHASE1 Not yet recruiting

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡